<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37202336</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-7500</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Digital health</Title><ISOAbbreviation>Lancet Digit Health</ISOAbbreviation></Journal><ArticleTitle>Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations.</ArticleTitle><Pagination><StartPage>e421</StartPage><EndPage>e434</EndPage><MedlinePgn>e421-e434</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2589-7500(23)00056-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2589-7500(23)00056-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Self-reported symptom studies rapidly increased understanding of SARS-CoV-2 during the COVID-19 pandemic and enabled monitoring of long-term effects of COVID-19 outside hospital settings. Post-COVID-19 condition presents as heterogeneous profiles, which need characterisation to enable personalised patient care. We aimed to describe post-COVID-19 condition profiles by viral variant and vaccination status.</AbstractText><AbstractText Label="METHODS">In this prospective longitudinal cohort study, we analysed data from UK-based adults (aged 18-100 years) who regularly provided health reports via the Covid Symptom Study smartphone app between March 24, 2020, and Dec 8, 2021. We included participants who reported feeling physically normal for at least 30 days before testing positive for SARS-CoV-2 who subsequently developed long COVID (ie, symptoms lasting longer than 28 days from the date of the initial positive test). We separately defined post-COVID-19 condition as symptoms that persisted for at least 84 days after the initial positive test. We did unsupervised clustering analysis of time-series data to identify distinct symptom profiles for vaccinated and unvaccinated people with post-COVID-19 condition after infection with the wild-type, alpha (B.1.1.7), or delta (B.1.617.2 and AY.x) variants of SARS-CoV-2. Clusters were then characterised on the basis of symptom prevalence, duration, demography, and previous comorbidities. We also used an additional testing sample with additional data from the Covid Symptom Study Biobank (collected between October, 2020, and April, 2021) to investigate the effects of the identified symptom clusters of post-COVID-19 condition on the lives of affected people.</AbstractText><AbstractText Label="FINDINGS">We included 9804 people from the COVID Symptom Study with long COVID, 1513 (15%) of whom developed post-COVID-19 condition. Sample sizes were sufficient only for analyses of the unvaccinated wild-type, unvaccinated alpha variant, and vaccinated delta variant groups. We identified distinct profiles of symptoms for post-COVID-19 condition within and across variants: four endotypes were identified for infections due to the wild-type variant (in unvaccinated people), seven for the alpha variant (in unvaccinated people), and five for the delta variant (in vaccinated people). Across all variants, we identified a cardiorespiratory cluster of symptoms, a central neurological cluster, and a multi-organ systemic inflammatory cluster. These three main clusers were confirmed in a testing sample. Gastrointestinal symptoms clustered in no more than two specific phenotypes per viral variant.</AbstractText><AbstractText Label="INTERPRETATION">Our unsupervised analysis identified different profiles of post-COVID-19 condition, characterised by differing symptom combinations, durations, and functional outcomes. Our classification could be useful for understanding the distinct mechanisms of post-COVID-19 condition, as well as for identification of subgroups of individuals who might be at risk of prolonged debilitation.</AbstractText><AbstractText Label="FUNDING">UK Government Department of Health and Social Care, Chronic Disease Research Foundation, The Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging &amp; Artificial Intelligence Centre for Value-Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, UK Alzheimer's Society, and ZOE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canas</LastName><ForeName>Liane S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK. Electronic address: liane.dos_santos_canas@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molteni</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudre</LastName><ForeName>Carole H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, London, UK; Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerfoot</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rjoob</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capdevila Pujol</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ZOE, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polidori</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ZOE, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ZOE, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;sterdahl</LastName><ForeName>Marc F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whiston</LastName><ForeName>Ronan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheetham</LastName><ForeName>Nathan J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowyer</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spector</LastName><ForeName>Tim D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammers</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Emma L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK; Department of Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ourselin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steves</LastName><ForeName>Claire J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Twin Research &amp; Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modat</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering &amp; Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Digit Health</MedlineTA><NlmUniqueID>101751302</NlmUniqueID><ISSNLinking>2589-7500</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="N">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests AM, LP, and JCP are employees of ZOE. AM and JCP hold stocks in ZOE. CJS reports consultancy fees from ZOE. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37202336</ArticleId><ArticleId IdType="pmc">PMC10187990</ArticleId><ArticleId IdType="doi">10.1016/S2589-7500(23)00056-0</ArticleId><ArticleId IdType="pii">S2589-7500(23)00056-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>UK National Health Service  Coronavirus (COVID-19) 2020. https://www.nhs.uk/conditions/coronavirus-covid-19/</Citation></Reference><Reference><Citation>Ayoubkhani D, Pawelek P. Office for National statistics; London: 2022. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK 3 February 2022.</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>UK National Institute for Health and Care Excellence  COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. https://www.nice.org.uk/guidance/NG188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Office for National Statistics  Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 22 June 2022. 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6may2022</Citation></Reference><Reference><Citation>Nurek M, Rayner C, Freyer A, et al. Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study. Br J Gen Pract. 2021;71:e815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510689</ArticleId><ArticleId IdType="pubmed">34607799</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine. 2022;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Social Care. Throup M, Javid S, Johnson B. UK marks one year since deploying world's first COVID-19 vaccine. 2021. https://www.gov.uk/government/news/uk-marks-one-year-since-deploying-worlds-first-covid-19-vaccine</Citation></Reference><Reference><Citation>Yong SJ, Liu S. Proposed subtypes of post-COVID-19 syndrome (or long-COVID) and their respective potential therapies. Rev Med Virol. 2021;32</Citation><ArticleIdList><ArticleId IdType="pubmed">34888989</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen JH, Tomlinson C, Hollings S, et al. COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Lancet Digit Health. 2022;4:e542&#x2013;e557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179175</ArticleId><ArticleId IdType="pubmed">35690576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesuthasan A, Massey F, Manji H, Zandi MS, Wiethoff S. Emerging potential mechanisms and predispositions to the neurological manifestations of COVID-19. J Neurol Sci. 2021;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8332920</ArticleId><ArticleId IdType="pubmed">34391037</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield E, Coffey C, Zhang H, et al. Axes of prognosis: identifying subtypes of COVID-19 outcomes. AMIA Annu Symp Proc. 2022;2021:1198&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861682</ArticleId><ArticleId IdType="pubmed">35308999</ArticleId></ArticleIdList></Reference><Reference><Citation>Drew DA, Nguyen LH, Steves CJ, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368:1362&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200009</ArticleId><ArticleId IdType="pubmed">32371477</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>COG-UK  Variants of concern (VOC) and under investigation (VUI) and any other variant by weeks and days. 2023. https://sars2.cvr.gla.ac.uk/cog-uk/</Citation></Reference><Reference><Citation>Sudre CH, Lee KA, Lochlainn MN, et al. Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID Symptom Study app. Sci Adv. 2021;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978420</ArticleId><ArticleId IdType="pubmed">33741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. Multivariate time series clustering based on common principal component analysis. Neurocomputing. 2019;349:239&#x2013;247.</Citation></Reference><Reference><Citation>Murray B, Kerfoot E, Chen L, et al. Accessible data curation and analytics for international-scale citizen science datasets. Sci Data. 2021;8:297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608807</ArticleId><ArticleId IdType="pubmed">34811392</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer RCE, Huggins C, Toms R, et al. Characterising patterns of COVID-19 and long COVID symptoms: evidence from nine UK longitudinal studies. Eur J Epidemiol. 2023;38:199&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860244</ArticleId><ArticleId IdType="pubmed">36680646</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal SM, Landers DB, Hollenberg SM, et al. Prospective evaluation of autonomic dysfunction in post-acute sequela of COVID-19. J Am Coll Cardiol. 2022;79:2325&#x2013;2330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976261</ArticleId><ArticleId IdType="pubmed">35381331</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J. Clues to long COVID. Science. 2022;376:1271&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709281</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Do vaccines protect from long COVID? Lancet Respir Med. 2022;10:e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776281</ArticleId><ArticleId IdType="pubmed">35065716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J. 2022;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas LS, Sudre CH, Capdevila Pujol J, et al. Early detection of COVID-19 in the UK using self-reported symptoms: a large-scale, prospective, epidemiological surveillance study. Lancet Digit Health. 2021;3:e587&#x2013;e598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8321433</ArticleId><ArticleId IdType="pubmed">34334333</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>